Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Mesothelioma
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Mesothelioma
Provide the treatment for incurable mesothelioma.
Evaluate the adverse effects and tolerance of Antineoplaston A10 and AS2-1 in these patients.
Inclusion Criteria:
 |
Patients who have histologically confirmed, mesothelioma, stage IV and are unlikely to have a curative respond to existing standard regimen including surgery, radiation therapy and chemotherapy. |
|
There will be no exclusion based on tumor size or systemic metastases. |
|
Radiological evidence of tumor by gadolinium-enhanced MRI or contrast-enhanced CT scan, chest x-ray, or radionuclide scan, if necessary, performed within 14 days before initiating the treatment. |
|
Patients who have previously received radiation therapy, chemotherapy, immunotherapy or cytodifferentiating agent are eligible. |
|
Patients who did not receive standard therapy are eligible. |
Location/Contact Information:
Salim Qazizadeh M.D.
S. R. Burzynski Clinic
9432 Old Katy, Suite 200
Houston, TX 77055
Telephone: 713-335-5697
Fax: 713-335-5699
Email: info@burzynskiclinic.com
